Pfizer: ABRYSVO vaccine approved in US

(CercleFinance.com) - Pfizer announced last night that the US FDA has approved ABRYSVO, its respiratory syncytial virus vaccine, the company's bivalent prefusion F vaccine, for the prevention of lower respiratory tract disease (LRD) caused by RSV in people aged 18 to 59.


ABRYSVO now offers the broadest vaccine indication for adults, which previously included people aged 60 and over. In addition, it remains the only RSV vaccine approved for pregnant women from 32 to 36 weeks' gestation to protect infants from birth to 6 months of age.

After decades of research, we now have the opportunity to help alleviate the burden of RSV in this high-risk adult population, Pfizer said.

With this approval, we are proud that ABRYSVO is now the only RSV vaccine indicated for adults aged 18-49 at increased risk of contracting the disease, expanding its existing indications for the elderly and pregnant women, it adds.


Copyright (c) 2024 CercleFinance.com. All rights reserved.